To report the efficacy and tolerability of brivaracetam (BRV) in add-on therapy in pediatric patients with severe drug-resistant epilepsy. Prognostic factors of clinical outcome were also analyzed.
Brivaracetam add-on treatment in pediatric patients with severe drug-resistant epilepsy: Italian real-world evidence / Russo, Angelo; Pruccoli, Jacopo; Cesaroni, Carlo Alberto; Belotti, Laura Maria Beatrice; Zenesini, Corrado; Bonanni, Paolo; Boni, Antonella; Cesaroni, Elisabetta; Coppola, Giangennaro; Cordelli, Duccio Maria; Danieli, Alberto; Mancardi, Maria Margherita; Marchese, Francesca; Matricardi, Sara; Messana, Tullio; Nocera, Giovanna Martina; Operto, Francesca Felicia; Pellino, Giuditta; Reina, Federica; Vanadia, Francesca; Verrotti, Alberto; Striano, Pasquale. - In: SEIZURE. - ISSN 1059-1311. - ELETTRONICO. - 102:(2022), pp. 120-124. [10.1016/j.seizure.2022.10.001]
Brivaracetam add-on treatment in pediatric patients with severe drug-resistant epilepsy: Italian real-world evidence
Russo, Angelo
;Pruccoli, Jacopo;Cesaroni, Carlo Alberto;Belotti, Laura Maria Beatrice;Zenesini, Corrado;Cordelli, Duccio Maria;
2022
Abstract
To report the efficacy and tolerability of brivaracetam (BRV) in add-on therapy in pediatric patients with severe drug-resistant epilepsy. Prognostic factors of clinical outcome were also analyzed.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
